Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation

Epidemiological studies reveal that marijuana increases the risk of cardiovascular disease (CVD); however, little is known about the mechanism. Δ9-tetrahydrocannabinol (Δ9-THC), the psychoactive component of marijuana, binds to cannabinoid receptor 1 (CB1/CNR1) in the vasculature and is implicated in CVD. A UK Biobank analysis found that cannabis was an risk factor for CVD. We found that marijuana smoking activated inflammatory cytokines implicated in CVD. In silico virtual screening identified genistein, a soybean isoflavone, as a putative CB1 antagonist. Human-induced pluripotent stem cell-derived endothelial cells were used to model Δ9-THC-induced inflammation and oxidative stress via NF-κB signaling. Knockdown of the CB1 receptor with siRNA, CRISPR interference, and genistein attenuated the effects of Δ9-THC. In mice, genistein blocked Δ9-THC-induced endothelial dysfunction in wire myograph, reduced atherosclerotic plaque, and had minimal penetration of the central nervous system. Genistein is a CB1 antagonist that attenuates Δ9-THC-induced atherosclerosis.

You can read the full study published in Cell here: https://doi.org/10.1016/j.cell.2022.04.005

For more information on the International Academy on the Science and Impact of Cannabis, and to join, please visit www.IASIC1.org.

Visit the IASIC Library here (https://iasic1.org/library/). The IASIC Library is intended as a user-friendly reference of the published medical literature.

Like this article?

Share on Facebook
Share on Twitter
Share on Linkdin
Share on Pinterest

Leave a comment

Related Posts

Federal Regulations of Cannabis for Public Health in the United States

Millions of Americans use cannabis in moderation each month without any problems. However, evidence is mounting of harmful physical and mental health effects associated with heavy or long-term regular cannabis use. At the same time, existing legal markets in the United States are making high-potency cannabis products available to adult consumers. Recent international recommendations suggest

Vaping May Open the Door to Cannabis Use in Teens

Adolescents who used e-cigarettes were significantly more likely to become new smokers of cannabis shortly thereafter, a cohort study found. Cannabis-naive adolescents reporting ever vaping at baseline were more than twice as likely to report also using cannabis when surveyed a year later (adjusted RR 2.57 vs nonusers of e-cigarettes, 95% CI 2.04-3.09), reported Ruoyan

Clinical management of cannabis withdrawal

Cannabis withdrawal is a well-characterized phenomenon that occurs in approximately half of regular and dependent cannabis users after abrupt cessation or significant reductions in cannabis products that contain Δ9-tetrahydrocannabinol (THC). This review describes the diagnosis, prevalence, course and management of cannabis withdrawal and highlights opportunities for future clinical research. Read the full study published in

Association of cannabis potency with mental ill health and addiction: a systematic review

Cannabis potency, defined as the concentration of Δ9-tetrahydrocannabinol (THC), has increased internationally, which could increase the risk of adverse health outcomes for cannabis users. We present, to our knowledge, the first systematic review of the association of cannabis potency with mental health and addiction (PROSPERO, CRD42021226447). We searched Embase, PsycINFO, and MEDLINE (from database inception

Highly potent weed creating marijuana addicts worldwide, study says

Higher concentrations of tetrahydrocannabinol or THC — the part of the marijuana plant that makes you high — are causing more people to become addicted in many parts of the world, a new review of studies found. Read the full article from CNN here: https://amp.cnn.com/cnn/2022/07/25/health/marijuana-potency-addiction-study-wellness/index.html For more information on the International Academy on the Science

Scroll to Top